Question-and-Answer Session
Operator
(Operator Instruction) Your first question comes from Randall Stanicky of Goldman Sachs.
Randall Stanicky - Goldman Sachs
Hey, guys. Thanks a lot for the question and again congratulations on getting the deal with Teva in place. I just have one question and John I was hoping maybe you could just expand a little bit more on your outlook for Nasulin. You've provided a lot of detail there, and as you talk to partners, potential partners, around that product can you maybe give us a sense of how some of those discussions are going as that product continues to move along? And then, secondly you referred on the call in your prepared remarks to your CPE-215 technology and also obviously, leveraging that. Can you maybe expand a little bit more in terms of some of the opportunities to do that going forward?
John Sedor
Yes, Randall, first let me just talk, in previous conference calls we've talked about being in discussions on Nasulin with other companies that are interested in that. I mentioned in my remarks that one of the things that we're focusing on is the pathway for Phase III clinicals and then going forward on that. These discussions, as I mentioned in our remarks, have been discussed with potential partners and clearly they're looking as we are, to the outcomes of the clinical process that we have ongoing.
And as they go forward, those discussions continue to go. With respect to CPE-215, we are excited about that platform and the fact that it does have the ability to move these molecules through biological membranes, we are constantly getting either people talking to us about it or in discussions with people on how we can affect their molecule. But beyond that, I would rather -- I don't think that I can go into much discussion on it.
Randall Stanicky - Goldman Sachs
Maybe just let me follow-up and again, I want to be sensitive to what you can and cannot talk about. I think clearly people understand at this point that the value of the generics piece of the business given the contract in place. So clearly, the incremental value is sort of the rest of the business. So, just in terms of -- I guess some of the other things that you have going on, obviously, Testim is fairly obvious and with the reissue there a little bit more visible.
- To read the full transcript on Seeking Alpha, click here »
